GM PHARMA Pursuing Strategic Partnerships

GM PHARMA is an international pharmaceutical company originating from Georgia with medicines and food supplements manufactured both in GMP-certified plants across Western Europe (Germany, Greece, Spain, Switzerland, Italy, Sweden, Portugal, etc.) and in its own GMP-certified facility in Georgia.

As the first Georgian manufacturer of medicines and the largest pharmaceutical producer in the South Caucasus region, the company operates a full-cycle manufacturing plant specializing in oral solid dosage forms. This process is carried out in full compliance with the national and international standards: National GMP, GMP PIC/S, ISO 9001:2015, ISO 17025:2010 and NSF.

GM PHARMA is among the fastest-growing pharmaceutical companies in the South Caucasus and Central Asia. Beyond Georgia, the company has representative offices in seven CIS countries (Uzbekistan, Kyrgyzstan, Tajikistan, Armenia, Moldova, Azerbaijan and Kazakhstan) and is expanding registration and market access activities in Ukraine, Belarus, Turkmenistan and Mongolia.

Each year, more than 12 million patients benefit from GM PHARMA medicines and dietary supplements – evidence of the trust the company has earned from consumers and healthcare professionals alike.

GM PHARMA is deeply committed to innovation, having established a robust R&D and product development strategy. With 18 active research projects and over 30 new initiatives planned for 2025, the company continues to drive forward-thinking growth.

Strategic annual investments and a strong pipeline of new drugs underscore GM PHARMA’s unwavering focus on operational excellence, regulatory compliance and its long-term vision to lead through science and technology.

Looking ahead, the company’s top strategic priority is to obtain EU GMP certification – solidifying its transformation from a regional leader into a truly global pharmaceutical powerhouse and enabling geographic expansion into new territories (e.g., EU countries, South-east Asia, South & Central Americas).

At GM PHARMA, the mission is clear – Innovating for healthier tomorrows. Guided by this vision, the company actively pursues in-licensing (EU CTD dossier registered across the EU), formulation & analytical development, technology transfer and contract manufacturing opportunities with partners who share the commitment to advancing global health.

Should you be interested, kindly reach out to us via email

Key Products for In-Licensing, Development and Technology Transfer Evaluation: